These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 19850376)

  • 1. Assessment of the putative binding conformation of a pyrazolopyridine class of inhibitors of MAPKAPK2 using computational studies.
    Miglani R; Cliffe IA; Voleti SR
    Eur J Med Chem; 2010 Jan; 45(1):98-105. PubMed ID: 19850376
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structural analysis of an MK2-inhibitor complex: insight into the regulation of the secondary structure of the Gly-rich loop by TEI-I01800.
    Fujino A; Fukushima K; Namiki N; Kosugi T; Takimoto-Kamimura M
    Acta Crystallogr D Biol Crystallogr; 2010 Jan; 66(Pt 1):80-7. PubMed ID: 20057052
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 2,4-Diaminopyrimidine MK2 inhibitors. Part I: Observation of an unexpected inhibitor binding mode.
    Argiriadi MA; Ericsson AM; Harris CM; Banach DL; Borhani DW; Calderwood DJ; Demers MD; Dimauro J; Dixon RW; Hardman J; Kwak S; Li B; Mankovich JA; Marcotte D; Mullen KD; Ni B; Pietras M; Sadhukhan R; Sousa S; Tomlinson MJ; Wang L; Xiang T; Talanian RV
    Bioorg Med Chem Lett; 2010 Jan; 20(1):330-3. PubMed ID: 19919896
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of a fluorescent-tagged kinase assay system for the detection and characterization of allosteric kinase inhibitors.
    Simard JR; Getlik M; Grütter C; Pawar V; Wulfert S; Rabiller M; Rauh D
    J Am Chem Soc; 2009 Sep; 131(37):13286-96. PubMed ID: 19572644
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 4-Substituted-7-azaindoles bearing a ureidobenzofuranone moiety as potent and selective, ATP-competitive inhibitors of the mammalian target of rapamycin (mTOR).
    Tsou HR; MacEwan G; Birnberg G; Zhang N; Brooijmans N; Toral-Barza L; Hollander I; Ayral-Kaloustian S; Yu K
    Bioorg Med Chem Lett; 2010 Apr; 20(7):2259-63. PubMed ID: 20188551
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structural analysis of carboline derivatives as inhibitors of MAPKAP K2 using 3D QSAR and docking studies.
    Nayana RS; Bommisetty SK; Singh K; Bairy SK; Nunna S; Pramod A; Muttineni R
    J Chem Inf Model; 2009 Jan; 49(1):53-67. PubMed ID: 19119997
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structure-based lead identification of ATP-competitive MK2 inhibitors.
    Barf T; Kaptein A; de Wilde S; van der Heijden R; van Someren R; Demont D; Schultz-Fademrecht C; Versteegh J; van Zeeland M; Seegers N; Kazemier B; van de Kar B; van Hoek M; de Roos J; Klop H; Smeets R; Hofstra C; Hornberg J; Oubrie A
    Bioorg Med Chem Lett; 2011 Jun; 21(12):3818-22. PubMed ID: 21565500
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structural basis for a high affinity inhibitor bound to protein kinase MK2.
    Hillig RC; Eberspaecher U; Monteclaro F; Huber M; Nguyen D; Mengel A; Muller-Tiemann B; Egner U
    J Mol Biol; 2007 Jun; 369(3):735-45. PubMed ID: 17449059
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multiple and single binding modes of fragment-like kinase inhibitors revealed by molecular modeling, residue type-selective protonation, and nuclear overhauser effects.
    Constantine KL; Mueller L; Metzler WJ; McDonnell PA; Todderud G; Goldfarb V; Fan Y; Newitt JA; Kiefer SE; Gao M; Tortolani D; Vaccaro W; Tokarski J
    J Med Chem; 2008 Oct; 51(19):6225-9. PubMed ID: 18771253
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Computational proteomics of biomolecular interactions in the sequence and structure space of the tyrosine kinome: deciphering the molecular basis of the kinase inhibitors selectivity.
    Verkhivker GM
    Proteins; 2007 Mar; 66(4):912-29. PubMed ID: 17173284
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structure of the β-form of human MK2 in complex with the non-selective kinase inhibitor TEI-L03090.
    Fujino A; Fukushima K; Kubota T; Matsumoto Y; Takimoto-Kamimura M
    Acta Crystallogr Sect F Struct Biol Cryst Commun; 2013 Dec; 69(Pt 12):1344-8. PubMed ID: 24316826
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 2,4-Diaminopyrimidine MK2 inhibitors. Part II: Structure-based inhibitor optimization.
    Harris CM; Ericsson AM; Argiriadi MA; Barberis C; Borhani DW; Burchat A; Calderwood DJ; Cunha GA; Dixon RW; Frank KE; Johnson EF; Kamens J; Kwak S; Li B; Mullen KD; Perron DC; Wang L; Wishart N; Wu X; Zhang X; Zmetra TR; Talanian RV
    Bioorg Med Chem Lett; 2010 Jan; 20(1):334-7. PubMed ID: 19926477
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of 3,6-dihydro-2H-pyran as a morpholine replacement in 6-aryl-1H-pyrazolo[3,4-d]pyrimidines and 2-arylthieno[3,2-d]pyrimidines: ATP-competitive inhibitors of the mammalian target of rapamycin (mTOR).
    Kaplan J; Verheijen JC; Brooijmans N; Toral-Barza L; Hollander I; Yu K; Zask A
    Bioorg Med Chem Lett; 2010 Jan; 20(2):640-3. PubMed ID: 19963384
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structures of human MST3 kinase in complex with adenine, ADP and Mn2+.
    Ko TP; Jeng WY; Liu CI; Lai MD; Wu CL; Chang WJ; Shr HL; Lu TJ; Wang AH
    Acta Crystallogr D Biol Crystallogr; 2010 Feb; 66(Pt 2):145-54. PubMed ID: 20124694
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel 3-aminopyrazole inhibitors of MK-2 discovered by scaffold hopping strategy.
    Velcicky J; Feifel R; Hawtin S; Heng R; Huppertz C; Koch G; Kroemer M; Moebitz H; Revesz L; Scheufler C; Schlapbach A
    Bioorg Med Chem Lett; 2010 Feb; 20(3):1293-7. PubMed ID: 20060294
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pyrazolopyrimidines as highly potent and selective, ATP-competitive inhibitors of the mammalian target of rapamycin (mTOR): optimization of the 1-substituent.
    Curran KJ; Verheijen JC; Kaplan J; Richard DJ; Toral-Barza L; Hollander I; Lucas J; Ayral-Kaloustian S; Yu K; Zask A
    Bioorg Med Chem Lett; 2010 Feb; 20(4):1440-4. PubMed ID: 20089401
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rapid generation of a high quality lead for transforming growth factor-beta (TGF-beta) type I receptor (ALK5).
    Goldberg FW; Ward RA; Powell SJ; Debreczeni JE; Norman RA; Roberts NJ; Dishington AP; Gingell HJ; Wickson KF; Roberts AL
    J Med Chem; 2009 Dec; 52(23):7901-5. PubMed ID: 19736928
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vivo and in vitro SAR of tetracyclic MAPKAP-K2 (MK2) inhibitors. Part II.
    Revesz L; Schlapbach A; Aichholz R; Dawson J; Feifel R; Hawtin S; Littlewood-Evans A; Koch G; Kroemer M; Möbitz H; Scheufler C; Velcicky J; Huppertz C
    Bioorg Med Chem Lett; 2010 Aug; 20(15):4719-23. PubMed ID: 20591669
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of c-Met kinase domain complexes: a new specific catalytic site receptor model for defining binding modes of ATP-competitive ligands.
    Asses Y; Leroux V; Tairi-Kellou S; Dono R; Maina F; Maigret B
    Chem Biol Drug Des; 2009 Dec; 74(6):560-70. PubMed ID: 19909299
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structure of Mycobacterium tuberculosis PknB supports a universal activation mechanism for Ser/Thr protein kinases.
    Young TA; Delagoutte B; Endrizzi JA; Falick AM; Alber T
    Nat Struct Biol; 2003 Mar; 10(3):168-74. PubMed ID: 12548283
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.